Gilead Sciences, Inc. (NASDAQ: GILD ) fell 7.8% after reporting weaker-than-expected earnings and revenues for the first quarter. Despite the addition of verbiage saying the Fed would treat its 2% inflation target as symmetrical (in that they would allow an overshoot for a time, winking at a status quo pace of rate hikes) the market interpreted the statement as carrying a hawkish bias pushing the dollar higher and stocks lower. 10 Small-Cap Stocks With Large-Cap Potential Currently, the futures market assigns 50-50 odds of four quarter-point rate hikes before the end of the year.